Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(24)00262-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How the US National Institutes of Health is confronting health threats in a changing world.
Lancet
December 2024
Office of the Director, National Institutes of Health, Bethesda, MD, USA.
The Oncology QCARD Initiative: Fostering efficient evaluation of initial real-world data proposals.
Pharmacoepidemiol Drug Saf
November 2024
Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Purpose: The oncology quality, characterization, and assessment of real-world data (Oncology QCARD) Initiative was formed to develop a set of minimum study design and data elements needed to evaluate the fitness of the real-world data (RWD) source(s) proposed in an initial study concept as part of early interaction with scientific reviewers.
Methods: A multidisciplinary executive committee (EC) was established to guide the Oncology QCARD Initiative. The EC conducted a landscape review of published literature, guidances, and guidelines to evaluate relevant dimensions of data quality measurement.
Opportunities for Innovation in Smoking Cessation Therapies: A Perspective From the National Institutes of Health and U.S. Food and Drug Administration.
Ann Intern Med
October 2024
National Institutes of Health, Bethesda, Maryland (W.M.C., E.S.H., M.M.B.).
Applied research won't flourish without basic science.
Elife
September 2024
National Institutes of Health, Bethesda, United States.
Three senior figures at the US National Institutes of Health explain why the agency remains committed to supporting basic science and research.
View Article and Find Full Text PDFHigh-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistance.
Commun Med (Lond)
July 2024
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Article Synopsis
- CEACAM1 is a cell surface protein that affects immune responses, but its role in tumors is not well understood.
- The study used specialized antibodies to analyze the presence of CEACAM1 alongside PD1 and PD-L1 in various immune cells from melanoma patients and healthy controls.
- Results showed high levels of CEACAM1 on immune cells in melanoma patients, particularly in those resistant to treatment, indicating potential pathways for targeted therapies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!